Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Myriad Genetics, Inc. [MYGN]
Reports for Purchase
Showing records 181 - 200 ( 241 total )
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Terminating Coverage Due to Analyst Departure.
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: CMS Releases Preliminary Payment Methodology Continued Uncertainty for BRACAnalysis Reimbursement Until at Least November, Maintain NEUTRAL
Provider: COLLIERS SECURITIES
Analyst: HUSAIN J
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: CMS Releases Preliminary Payment Methodology Continued Uncertainty for BRACAnalysis Reimbursement Until at Least November, Maintain NEUTRAL
Provider: COLLIERS SECURITIES
Analyst: HUSAIN J
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: 2013 Reimbursement Uncertainty for BRACAnalysis Takes Us to the Sidelines Downgrading to NEUTRAL
Provider: COLLIERS SECURITIES